SEC Comment Letter for CYTOKINETICS INC (CYTK) (CIK 0001061983) (CYTK) — Feb 5, 2015

CYTOKINETICS INC (CYTK) (CIK 0001061983)
Date: Feb. 5, 2015 · CIK: 0001061983 · Accession: 0000000000-15-007094

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-50633

Date

February 4, 2015

Author

/s/ Joel Parker

Form

UPLOAD

Company

CYTOKINETICS INC (CYTK) (CIK 0001061983)

Letter

February 4, 2015 Via E -mail Sharon A. Barbari Chief Financial Officer Cytokinetics, Inc. 280 East Grand Avenue South San Francisco, CA 94080

Re: Cytokinetics, Inc. Form 10 -K for the Fiscal Year Ended December 31, 2013 Filed March 7 , 2014 File No. 000-50633

Dear Ms. Barbari :

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information in the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,
/s/ Joel Parker

Show Raw Text

February 4, 2015

Via E -mail
Sharon A. Barbari
Chief Financial Officer
Cytokinetics, Inc.
280 East Grand Avenue
South San Francisco, CA  94080

Re: Cytokinetics, Inc.
 Form 10 -K for the Fiscal Year Ended December  31, 2013
 Filed March 7 , 2014
 File No. 000-50633

Dear Ms. Barbari :

We have completed our review of your filing.   We remind you that our comments or
changes to disclosure in response to our comments do not foreclose the Commission from taking
any action with respect to the company or the filing and the company may not assert staff
comments as a defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United  States.   We urge all persons who are responsible for the
accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the
information in the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

       /s/ Joel Parker

Joel Parker
Accounting Branch Chief

SecProbe.io